QuidelOrtho (NASDAQ:QDEL) Releases Earnings Results

by · The Markets Daily

QuidelOrtho (NASDAQ:QDEL – Get Free Report) issued its quarterly earnings data on Tuesday. The company reported $0.31 EPS for the quarter, topping analysts’ consensus estimates of $0.20 by $0.11, FiscalAI reports. QuidelOrtho had a positive return on equity of 4.88% and a negative net margin of 39.20%. The company had revenue of $618.90 million for the quarter, compared to analysts’ expectations of $627.83 million.

QuidelOrtho Stock Up 0.4%

Shares of NASDAQ:QDEL traded up $0.06 during midday trading on Tuesday, reaching $14.09. The company had a trading volume of 3,536,049 shares, compared to its average volume of 1,783,132. The stock has a market capitalization of $966.22 million, a P/E ratio of -0.91 and a beta of 0.79. The stock’s fifty day moving average price is $12.74 and its 200-day moving average price is $16.38. The company has a debt-to-equity ratio of 1.43, a current ratio of 1.39 and a quick ratio of 0.76. QuidelOrtho has a one year low of $9.92 and a one year high of $35.58.

Wall Street Analysts Forecast Growth

QDEL has been the topic of several analyst reports. Zacks Research upgraded QuidelOrtho from a “strong sell” rating to a “hold” rating in a report on Friday, October 9th. Citigroup upped their price target on QuidelOrtho from $13.00 to $18.00 and gave the stock a “neutral” rating in a report on Wednesday, July 8th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of QuidelOrtho in a research report on Thursday, October 15th. Four analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, QuidelOrtho presently has an average rating of “Reduce” and a consensus target price of $13.62.

Read Our Latest Stock Analysis on QDEL

QuidelOrtho Company Profile

(Get Free Report)

QuidelOrtho Corporation (NASDAQ:QDEL) is a global in vitro diagnostics company formed through the combination of Quidel Corporation and Ortho Clinical Diagnostics, a transaction completed in 2022. The company develops, manufactures and markets diagnostic technologies used to detect disease, guide treatment decisions and support blood-transfusion safety.

Its portfolio includes rapid immunoassays, molecular testing systems, clinical chemistry and immunohematology products, as well as laboratory automation solutions.

See Also